Table 1 Summary of the detected variants in the skeletal ciliopathy panel.

From: Unclassifiable short-rib thoracic dysplasia diagnosed using targeted gene panel sequencing

No.

DNA change

Protein change

Inheritance

ClinVer ID

CADD

Polyphen-2

SIFT

PROVEAN

M-CAP

Frequency (in Japanese population)#

Evaluation of pathogenicity (ACMG/AMP)

1

DYNC2H1 (NM_001080463.2) c.3404 A > T

p.Glu1135Val

M

SCV005077956

24.8

0.089 (Benign)

0.013 (Deleterious)

−5.45 (Deleterious)

0.096 (Possibly Pathogenic)

Likely Pathogenic Previously not reported (PM2, PM3, PP3, PP4)

2

DYNC2H1 (NM_001080463.2) c.5682_5683del

p.His1896Tyrfs*9

P

SCV000788364

33.0

0.00046

Pathogenic Previously reported (PVS1, PM2, PM3, PP5)

3

IFT140 (NM_014714.4) c.3602 G > A

p.Arg1201His

M

318004

22.8

0.028 (Benign)

0.152 (Tolerated)

−0.914 (Neutral)

0.010 (Likely Benign)

0.00619

Uncertain Significant (PM2, BP4)

4

IFT122 (NM_018262) c.457 A > C

p.Asn153His

P

25.9

0.771 (Possibly damaging)

−3.922 (Deleterious)

0.059 (Possibly Pathogenic)

0.00230

Uncertain Significant (PM2, PP3)

  1. The reference sequences used were DYNC2H1 (NM_001080463.2), IFT122 (NM_018262.4), and IFT140 (NM_014714.4).
  2. M maternal, P paternal, CADD combined annotation-dependent depletion (https://cadd.bihealth.org/), PolyPhen-2 polymorphism phenotyping v2 (http://genetics.bwh.harvard.edu/pph2), SIFT sorting intolerance from tolerant (http://sift-dna.org), PROVEAN protein variation effect analyzer (https://www.jcvi.org/research/provean), M-CAP Mendelian clinically applicable pathogenicity (http://bejerano.stanford.edu/mcap), # according to gnomAD v2.1.1, ACMG American College of Medical Genetics and Genomics, AMP Association for Molecular Pathology.